Suetonia C Palmer1, Sharon Gardner1, Marcello Tonelli2, Dimitris Mavridis3, David W Johnson4, Jonathan C Craig5, Richard French6, Marinella Ruospo7, Giovanni F M Strippoli8. 1. Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand. 2. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 3. Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, University Campus, Ioannina, Greece; Department of Primary Education, University of Ioannina, Ioannina, Greece. 4. Division of Medicine, Department of Nephrology, University of Queensland at the Princess Alexandra Hospital, Woolloongabba, QLD, Australia. 5. Sydney School of Public Health, The University of Sydney, NSW, Australia. 6. Whangarei Hospital, Whangarei, New Zealand. 7. Division of Nephrology and Transplantation, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Diaverum Medical Scientific Office, Diaverum Sweden AB, Lund, Sweden. 8. Sydney School of Public Health, The University of Sydney, NSW, Australia; Diaverum Medical Scientific Office, Diaverum Sweden AB, Lund, Sweden; Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. Electronic address: gfmstrippoli@gmail.com.
Abstract
BACKGROUND: Guidelines preferentially recommend noncalcium phosphate binders in adults with chronic kidney disease (CKD). We compare and rank phosphate-binder strategies for CKD. STUDY DESIGN: Network meta-analysis. SETTING & POPULATION: Adults with CKD. SELECTION CRITERIA FOR STUDIES: Randomized trials with allocation to phosphate binders. INTERVENTIONS: Sevelamer, lanthanum, iron, calcium, colestilan, bixalomer, nicotinic acid, and magnesium. OUTCOMES: The primary outcome was all-cause mortality. Additional outcomes were cardiovascular mortality, myocardial infarction, stroke, adverse events, serum phosphorus and calcium levels, and coronary artery calcification. RESULTS: 77 trials (12,562 participants) were included. Most (62 trials in 11,009 patients) studies were performed in a dialysis population. Trials were generally of short duration (median, 6 months) and had high risks of bias. All-cause mortality was ascertained in 20 studies during 86,744 patient-months of follow-up. There was no evidence that any drug class lowered mortality or cardiovascular events when compared to placebo. Compared to calcium, sevelamer reduced all-cause mortality (OR, 0.39; 95% CI, 0.21-0.74), whereas treatment effects of lanthanum, iron, and colestilan were not significant (ORs of 0.78 [95% CI, 0.16-3.72], 0.37 [95% CI, 0.09-1.60], and 0.55 [95% CI, 0.07-4.43], respectively). Lanthanum caused nausea, whereas sevelamer posed the highest risk for constipation and iron caused diarrhea. All phosphate binders lowered serum phosphorus levels to a greater extent than placebo, with iron ranked as the best treatment. Sevelamer and lanthanum posed substantially lower risks for hypercalcemia than calcium. LIMITATIONS: Limited testing of consistency; short follow-up. CONCLUSIONS: There is currently no evidence that phosphate-binder treatment reduces mortality compared to placebo in adults with CKD. It is not clear whether the higher mortality with calcium versus sevelamer reflects whether there is net harm associated with calcium, net benefit with sevelamer, both, or neither. Iron-based binders show evidence of greater phosphate lowering that warrants further examination in randomized trials.
BACKGROUND: Guidelines preferentially recommend noncalcium phosphate binders in adults with chronic kidney disease (CKD). We compare and rank phosphate-binder strategies for CKD. STUDY DESIGN: Network meta-analysis. SETTING & POPULATION: Adults with CKD. SELECTION CRITERIA FOR STUDIES: Randomized trials with allocation to phosphate binders. INTERVENTIONS: Sevelamer, lanthanum, iron, calcium, colestilan, bixalomer, nicotinic acid, and magnesium. OUTCOMES: The primary outcome was all-cause mortality. Additional outcomes were cardiovascular mortality, myocardial infarction, stroke, adverse events, serum phosphorus and calcium levels, and coronary artery calcification. RESULTS: 77 trials (12,562 participants) were included. Most (62 trials in 11,009 patients) studies were performed in a dialysis population. Trials were generally of short duration (median, 6 months) and had high risks of bias. All-cause mortality was ascertained in 20 studies during 86,744 patient-months of follow-up. There was no evidence that any drug class lowered mortality or cardiovascular events when compared to placebo. Compared to calcium, sevelamer reduced all-cause mortality (OR, 0.39; 95% CI, 0.21-0.74), whereas treatment effects of lanthanum, iron, and colestilan were not significant (ORs of 0.78 [95% CI, 0.16-3.72], 0.37 [95% CI, 0.09-1.60], and 0.55 [95% CI, 0.07-4.43], respectively). Lanthanum caused nausea, whereas sevelamer posed the highest risk for constipation and iron caused diarrhea. All phosphate binders lowered serum phosphorus levels to a greater extent than placebo, with iron ranked as the best treatment. Sevelamer and lanthanum posed substantially lower risks for hypercalcemia than calcium. LIMITATIONS: Limited testing of consistency; short follow-up. CONCLUSIONS: There is currently no evidence that phosphate-binder treatment reduces mortality compared to placebo in adults with CKD. It is not clear whether the higher mortality with calcium versus sevelamer reflects whether there is net harm associated with calcium, net benefit with sevelamer, both, or neither. Iron-based binders show evidence of greater phosphate lowering that warrants further examination in randomized trials.
Authors: Laura Sola; Nathan W Levin; David W Johnson; Roberto Pecoits-Filho; Harith M Aljubori; Yuqing Chen; Stefaan Claus; Allan Collins; Brett Cullis; John Feehally; Paul N Harden; Mohamed H Hassan; Fuad Ibhais; Kamyar Kalantar-Zadeh; Adeera Levin; Abdulkarim Saleh; Daneil Schneditz; Irma Tchokhonelidze; Rumeyza Turan Kazancioglu; Ahmed Twahir; Robert Walker; Anthony J O Were; Xueqing Yu; Fredric O Finkelstein Journal: Kidney Int Suppl (2011) Date: 2020-02-19
Authors: Ron Wald; Christian G Rabbat; Louis Girard; Amit X Garg; Karthik Tennankore; Jessica Tyrwhitt; Andrew Smyth; Andrea Rathe-Skafel; Peggy Gao; Andrea Mazzetti; Jackie Bosch; Andrew T Yan; Patrick Parfrey; Braden J Manns; Michael Walsh Journal: Clin J Am Soc Nephrol Date: 2017-05-26 Impact factor: 8.237
Authors: Julia Spoendlin; Julie M Paik; T Tsacogianis; Seoyoung C Kim; Sebastian Schneeweiss; Rishi J Desai Journal: JAMA Intern Med Date: 2019-06-01 Impact factor: 21.873
Authors: Nigel D Toussaint; Eugenia Pedagogos; Nicole M Lioufas; Grahame J Elder; Elaine M Pascoe; Sunil V Badve; Andrea Valks; Geoffrey A Block; Neil Boudville; James D Cameron; Katrina L Campbell; Sylvia S M Chen; Randall J Faull; Stephen G Holt; Dana Jackson; Meg J Jardine; David W Johnson; Peter G Kerr; Kenneth K Lau; Lai-Seong Hooi; Om Narayan; Vlado Perkovic; Kevan R Polkinghorne; Carol A Pollock; Donna Reidlinger; Laura Robison; Edward R Smith; Robert J Walker; Angela Yee Moon Wang; Carmel M Hawley Journal: J Am Soc Nephrol Date: 2020-09-11 Impact factor: 10.121
Authors: Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz Journal: Toxins (Basel) Date: 2018-06-12 Impact factor: 4.546